Eliaz Therapeutics (ETI), founded by Dr. Isaac Eliaz, focuses on harnessing his extensive expertise in Galectin-3 and Apheresis technology to create a cutting-edge therapeutic Apheresis device. This device aims to remove Galectin-3 from the bloodstream, which plays a pivotal role in various severe health conditions, particularly in Sepsis. Galectin-3 is linked to the exacerbation of inflammatory responses and immune dysregulation, including cytokine storms, which are critical factors in the progression and severity of sepsis.
The primary application of this technology is targeted at treating sepsis and its common complication, sepsis-induced Acute Kidney Injury (SA-AKI). Sepsis is a life-threatening response to infection that can lead to tissue damage, organ failure, and death. In the United States alone, sepsis leads to millions of hospitalizations each year, with a significant number of these cases progressing to AKI. This condition complicates the course of sepsis by impairing kidney function, potentially necessitating intensive treatments like dialysis or kidney transplantation.
Currently, there are no approved treatments that effectively prevent, alleviate, or expedite recovery from sepsis and its associated AKI. ETIs XGAL3 apheresis technology offers a potential breakthrough in sepsis treatment, aiming to improve patient management and outcomes dramatically, and offering hope for saving hundreds of thousands of lives each year.
